Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 195Prostatic Neoplasms, Castration-Resistant 20Neoplasm Metastasis 20Metastatic Castration Resistant Prostate Cancer 10Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Metastatic Castration-resistant Prostate Cancer 6Neoplasms 5Castration-resistant Prostate Cancer 5Breast Neoplasms 5Pancreatic Neoplasms 4Melanoma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Prostate Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Ovarian Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2

Interventions

Flow Cytometry 5Therapeutics 4Cyclophosphamide 4Tacrolimus 3Polymerase Chain Reaction 3Methylprednisolone 3Methotrexate 3Antilymphocyte Serum 3thymoglobulin 2ruxolitinib 2liposomal amphotericin B 2fludarabine phosphate 2abiraterone 2Sunitinib 2Psychiatric Rehabilitation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Mycophenolic Acid 2Itraconazole 2Immunologic Techniques 2Immunoenzyme Techniques 2Imatinib Mesylate 2Dexamethasone 2Caspofungin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Analgesia 2Amplified Fragment Length Polymorphism Analysis 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × enzalutamide × Genitourinary × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡